It has been two years since the World Health Organization (WHO) declared COVID-19 a pandemic. Pharmaceutical companies around the world have been working hard on research to treat COVID-19, which has claimed the lives of millions of people around the world. Pfizer, Merck, Sharp & Dom, Ridgeback, Roche, and Celltrion are representative pharmaceutical companies that have developed COVID-19 treatments.
EU-approved ‘Rekkorona’ and ‘Lonaprev’
“It will be an important turning point in the pandemic”
The European Medicines Agency (EMA) approved Roche’s Ronapreve and Celltrion’s Regkirona for the first time in the European Union. In announcing the approval results, the EMA said, “Lonaprev and Lekkorna are the first monoclonal antibody-based drugs to test positive for COVID-19.”
EU Health Director Stella Kyriakides said, “The approval of two treatments in Europe, which has so far relied on four vaccines, is an important turning point in the pandemic. I’m happy with this,” he said.
Pfizer’s Paxlovid Expects Emergency FDA Approval This Month
“The edible corona treatment ‘Paxlovid’ will also change the pandemic”
Pfizer announced on the 5th the clinical results of a treatment for COVID-19. It is a pill-type treatment that has been in development since March of last year. In a clinical trial of adult COVID-19 patients, the risk of hospitalization and death was reduced by 89%.
Pfizer conducted clinical trials on 1,219 adults in the Americas, Europe, Africa and Asia. This is the result of administering paxlobide and a placebo for 5 days every 12 hours after symptom onset.
In response to this achievement, Pfizer plans to send trial data to the U.S. Food and Drug Administration (FDA) as soon as possible to obtain emergency use approval. Pfizer CEO Albert Bourla said: “We expect approval before Thanksgiving, the 25th.
Merck’s Molnupiravir, the world’s first approval in the UK
“People who are vulnerable to disease, a situation where they can receive revolutionary treatment”
Molnupiravir from Merck USA is also available in pill form. A substance originally developed as a flu treatment by a research team at Emory University in the United States has become a treatment for COVID-19. Molnupiravir can be administered twice a day if there is at least one risk factor for severe severe COVID-19. Pharmaceutical companies such as Sharp & Dom and Ridgeback also participated in the clinical trial.
It was the first to receive approval from the UK Medicines and Healthcare Products Regulatory Authority. The UK Department of Health approved Molnupiravir, explaining that “the situation has shifted to a situation where people who are vulnerable to the disease and those without immunity will soon be able to receive revolutionary treatment.” The next goal is to get World Health Organization (WHO) approval.
“Therapeutics cannot replace the role of vaccines”
In addition, Roche is jointly developing ‘AT-527’, an oral (edible) antiviral drug for COVID-19 with Atea. A global multicenter phase 3 clinical trial is underway for mild and severe confirmed cases. After administration, ‘AT-527’ inhibits virus replication and prevents the progression of confirmed cases.
However, Felix Drexler, a professor at the University of Berlin in Germany, said in an interview with the press, “It is highly likely that paxlovide and molnupiravir are effective only in the early stages of infection. will be,” he explained.
Professor Drexler also said, “This is the same whether it is an antibody treatment or an oral treatment.
Copyright © Health Korea News Unauthorized reproduction and redistribution prohibited
Source: 헬스코리아뉴스 – 더뉴스 by www.hkn24.com.
*The article has been translated based on the content of 헬스코리아뉴스 – 더뉴스 by www.hkn24.com. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!